androstane-3,17-diol has been researched along with Bone Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauman, DR; Lin, HK; Peehl, DM; Penning, TM; Rizner, TL; Steckelbroeck, S | 1 |
| Bélanger, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F | 1 |
2 other study(ies) available for androstane-3,17-diol and Bone Cancer
| Article | Year |
|---|---|
Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
Topics: 17-Hydroxysteroid Dehydrogenases; Adenocarcinoma; Androstane-3,17-diol; Animals; Bone Neoplasms; COS Cells; Dihydrotestosterone; Epithelial Cells; Gene Expression Regulation, Enzymologic; Humans; Hydroxysteroid Dehydrogenases; In Vitro Techniques; Isoenzymes; Male; Prostate; Prostatic Neoplasms; Testosterone; Tumor Cells, Cultured | 2003 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstenedione; Androsterone; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dehydroepiandrosterone; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Kinetics; Luteinizing Hormone; Male; Pregnenolone; Progesterone; Prolactin; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |